Abstract Details

Title Tau Protein, beta-Amyloid 1-42 and Clusterin CSF Levels in Differential Diagnosis of Parkinsonian Syndrome with Dementia

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 156

Objective

Background BACKGROUND: The aim of this study was to identify in vivo markers that could help in differential diagnosis of these neurodegenerative (ND) diseases.

Design/Methods DESIGN/METHODS: Cerebrospinal fluid (CSF) levels of tau protein, beta-amyloid 1-42 and clusterin were assessed and then compared among patients with probable PD, PDD, DLB, AD and control group (CG). The studied group included 28 patients with PD, 14 with PDD, 14 with DLB, 17 with AD and 24 subjects as CG.

Results RESULTS: Across the patient groups, levels of beta-amyloid 1-42 levels were decreasing in the order PD > PDD > DLB > AD, whereas tau protein and the index tau protein/beta-amyloid 1-42 were increasing in the same order (PD < PDD < AD) except for DLB. In paired group comparisons, the following differences were statistically significant: higher levels of beta-amyloid1-42 in PD patients compared to DLB (p = 0.003) and AD (p < 0,0001); higher levels of tau protein in AD patients compared to PD patients (p = 0.026) and CG (p = 0.030); lower levels of the index tau protein/beta-amyloid 1-42 in PD patients compared to PDD (p = 0.004), DLB (p = 0.002) and AD (p = 0.0002). Significantly higher CSF levels of clusterin were found in PD patients (p=0.005) and PDD patients (p=0.052) compared to CG.

Conclusions CONCLUSIONS: The presented study shows that CSF of PDD and DLB patients manifests similar changes as those in AD patients, but some of these changes did not reach a level of statistical significance. Clusterin CSF levels could serve as a potentional marker for PDD and DLB differentiation.

Authors/Disclosures
Hana Prikrylova Vranova (Teva Pharmaceuticals CR) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Jan Mares, MD	Dr. Mares has nothing to disclose.
Petr Hlustik, MD, PhD (Palacký University Olomouc)	The institution of Prof. Hlustik has received research support from Czech Health Research Council (AZV CR).
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Petr Kanovsky, PhD	Dr. Kanovsky has nothing to disclose.

��ɫ��

��ɫ��